GLOBAL EXOSOME DIAGNOSTIC AND THERAPEUTIC MARKET FORECAST 2019-2027

The global exosome diagnostic and therapeutic market was valued at $61.08 million in 2018 & is estimated to generate net revenue of approximately $582.45 million by 2027, growing at a CAGR of 27.72%. Exosomes are defined as cell-derived vesicles that are present in all biological fluids, such as blood and urine. The exosome diagnostic and therapeutic market is primarily driven by the following factors:

• Increase in the pervasiveness of cancer
• Rising government and non-government initiatives
• Advancement in technology

The important drivers that are increasing the growth of the global exosome diagnostic and therapeutic market have been the advancement in technology, and an increase in the pervasiveness of cancer. Exosomes are nano-vesicles that comprise the proteins, DNA and RNA, which creates huge potential in the exosomes for the diagnosis of cancer. Introduction of innovative and technologically advanced exosome isolation procedures and isolation kits attract healthcare professionals and scientists to use exosome-based diagnostic and therapeutic products for their medical practices.

The application and products of exosome diagnostic and therapeutic market are used extensively for various purposes. The application comprises of diagnostic and therapeutic. Exosome-based diagnostics procedures use exosome as a biomarker for the diagnosis and progression of cancer. Some of the major exosome therapeutics includes regenerative capabilities, especially in the case of myocardial regeneration to repair cardiac tissues. Products of exosome diagnostic and therapeutic comprises of instrument, reagent, and software. Increasing research on exosome is the key driving factor for the global exosome instrument market. Reagents are used in isolation and culturing of exosomes in research and diagnostic laboratories. Innovative and advanced applications of exosome software in gene sequencing analysis have fueled the demand for this software across healthcare facilities.

Challenges faced in the usage of exosome and stringent regulation are the major factors hindering the exosome diagnostic and therapeutic market. The clinical development of exosomes as a “first-in-class” drug has a highly tractable manufacturing challenge. In the current scenario, the stringent regulatory standards affect the exosome diagnostic and therapeutic market growth, as it is a mandate to follow all regulatory standards.

The global exosome diagnostic and therapeutic market segments include application, product and end-user.

Application is segmented into:

• Diagnostic
• Therapeutic

Product is segmented into:

• Instrument
• Reagent
• Software

End-user is segmented into:

• Cancer Institute
• Hospital
• Diagnostic center
• Other End-user

This report covers the present market conditions and the growth prospects of the global exosome diagnostic and therapeutic market for 2019-2027 forecasting period and considered the revenue generated through the sales of exosome diagnostic and therapeutic for application, product and end-user to calculate the market size by considering 2018 as the base year.

Geographically, the global exosome diagnostic and the therapeutic market have been segmented on the basis of four major regions, which are:

• North America Exosome Diagnostic and Therapeutic Market : The United States & Canada
• Asia-Pacific Exosome Diagnostic and Therapeutic Market : China, India, Japan, Australia, South Korea & Rest of APAC
• Europe Exosome Diagnostic and Therapeutic Market : The United Kingdom, France, Germany, Italy, Spain & Rest of Europe
• Rest of World: Latin America & Middle East and Africa

The exosome diagnostic and therapeutic market in North America is expected to hold the largest share by 2027 possibilities of increased use of Exosome diagnostic and therapeutic. North America exosome diagnostic and therapeutic market constitutes approximately 41% share. The U.S. is the largest market in North America and is expected to maintain this trend during the analysis period. This is due to well-developed healthcare infrastructure in the region, technological advancement in exosome isolation techniques, and the significant increase in the geriatric population. On the other hand, the Asia-Pacific market is anticipated to the fastest-growing region for the exosome diagnostic and therapeutic market.

The Asia-Pacific region includes Japan, China, India, Australia, South Korea, and other countries. Increase in demand for advanced healthcare services in the emerging economies, such as that of India and China, is the major factor driving the growth of the Asia-Pacific regional market. In addition, the increase in the prevalence of cancer and cardiac diseases coupled with a rise in population in these nations are expected to fuel the demand for exosome-based diagnostic procedures.

The exosome diagnostic and therapeutic market is segmented based on end-user which is sub-divided into cancer institute, hospital, diagnostic center, and other end-user. Cancer institutes are expected to be a leading end-user segment in the exosome therapeutic and diagnostic market. In hospitals, exosome-based devices are used in the diagnosis and management of various diseases. In the diagnosis and treatment of chronic diseases, exosomes play a significant role, as exosomes may promote the development or progression of chronic inflammatory lung diseases such as asthma, pulmonary fibrosis, and chronic obstructive pulmonary disease. Other end-users of exosome diagnostic & therapeutic products include pharmaceutical and life science industries, medical universities, nursing homes, and non-profit organizations. Biotech companies are widely adopting exosomes for delivering many types of molecules, such as proteins and nucleic acid, and as therapies.

The major market players of the global exosome diagnostic and therapeutic market are:

• Aethlon Medical, Inc.
• Exosome Diagnostics Inc.
• Hitachi Chemical Diagnostics, Inc.
• Qiagen N.V.
• Nanosomix Inc.

Company Profiles covers the analysis of important players. Aethlon Medical, Inc. is highly focused on the discovery of biomarkers based on exosomes to diagnose and monitor neurological diseases and cancer. The company focuses on the neurodegeneration market.

Nanosomix Inc.’s first assay, NSX Direct, uses neural-derived exosomes to detect elevated levels of two key proteins involved in the pathogenesis of AD (p-tau and amyloid beta).

Key findings of the global exosome diagnostic and therapeutic market:

• The diagnostic is the majorly used application
• The software segment is anticipated to grow at a significant rate
• Cancer institute’s hold the largest market share in terms of end-user